Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 20G7-D9 |
| Synonyms | |
| Therapy Description |
20G7-D9 is a monoclonal antibody that targets AXL, potentially resulting in decreased growth and metastasis of AXL-expressing tumors (PMID: 24240689, PMID: 27923843). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 20G7-D9 | AXL Antibody 5 | 20G7-D9 is a monoclonal antibody that targets AXL, potentially resulting in decreased growth and metastasis of AXL-expressing tumors (PMID: 24240689, PMID: 27923843). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | triple-receptor negative breast cancer | sensitive | 20G7-D9 | Preclinical - Pdx | Actionable | In a preclinical study, 20G7-D9 inhibited tumor growth in triple-negative breast cancer cell line xenograft models with high or moderate AXL expression and in AXL-expressing patient-derived xenograft (PDX) models (PMID: 27923843). | 27923843 |
| AXL over exp | triple-receptor negative breast cancer | sensitive | 20G7-D9 | Preclinical - Pdx | Actionable | In a preclinical study, 20G7-D9 inhibited migration and invasion of triple-negative breast cancer (TNBC) cell lines with high expression of AXL in culture, and inhibited tumor growth in TNBC cell line and patient-derived xenograft models with high AXL expression levels (PMID: 27923843). | 27923843 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|